CEO Joseph Burnett stated that ClearPoint Neuro ended 2025 on its strongest financial quarter of the year, highlighting "a newly acquired and commercialized neurocritical care product line and genuine ...

[Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, ...

William Wood, an analyst from B.Riley Financial, reiterated the Buy rating on ClearPoint Neuro (CLPT – Research Report). The associated price target is $10.00. William Wood’s rating is based on ...

SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

Award-winning PR firm providing strategy, media relations, and marketing communications campaigns to Nonaste SAN DIEGO--(BUSINESS WIRE)--Clearpoint Agency, an award-winning public relations firm, is ...

Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, ...

SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...